Clinical • Trial completion date • Trial primary completion date • Combination therapy
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
ER positive • HER-2 overexpression
|
fulvestrant • letrozole • exemestane • sacibertinib (Hemay022)